nivolumab,ipilimumab,cabozantinib
bms,ipsen
['gu ', 'solid tumor', 'ipi/', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', 'renal,(-adrenal)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabopoint', 'cabo ', 'nivo', 'ipsen']
wonderful presentation by #gu23 cabopoint: interim results from ph 2 study of cabo after cpi in pts w/ arcc 1st prospective trial large study rr of 30% post ipi/nivo &amp; 25% post vegf/ici tx show sequencing these agents is of benefit 
#PsyOnc @CettroOncologia | Former Postdoc Fellow & Visiting Scholar @cityofhope | @IPOSPsychoOncol BOD 2021-2023 | #GU23 FCOI: https://t.co/EOsx8e8OYz